(IFRX) InflaRx N.V. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IFRX) InflaRx N.V. Complete Analysis Pack
InflaRx N.V.: Business Model Canvas at a Glance
Unlock the full strategic blueprint behind InflaRx N.V.’s business model. This concise yet insightful Business Model Canvas maps how the company creates value, partners strategically, and positions itself in a competitive biotech market. Ideal for investors, analysts, and strategists—get the full version for deeper, company-specific insight.
Partnerships
Merck & Co. clinical trial collaboration
InflaRx N.V. works with Merck & Co. Inc. under a clinical trial collaboration and supply agreement that helps advance vilobelimab in oncology. The deal supports trial execution, drug supply, and patient access, reducing development friction while backing InflaRx's oncology pipeline.
Beijing Defengrei co-development
InflaRx’s co-development deal with Beijing Defengrei Biotechnology Co. Ltd. extends its pipeline work beyond its core Germany and United States base, giving the Company access to a 2-market development footprint. The tie-up also supports external collaboration on pipeline assets, which can help spread development risk and open local execution channels in China.
Clinical trial sites
InflaRx N.V. relies on clinical trial sites to run Phase IIa, Phase II, and Phase III studies, especially in rare disease and oncology programs. These centers handle patient enrollment, dosing, safety monitoring, and endpoint capture, so site quality directly affects speed, data quality, and trial success.
Investigators and specialists
Dermatology, immunology, rheumatology, and oncology specialists are key partners for InflaRx N.V. because they help choose the right rare diseases, shape trial protocols, and manage high-risk patients. Their input also boosts scientific credibility in complex programs such as complement-driven inflammation, where strong investigator backing can matter as much as the data.
- Disease selection and protocol design
- Patient safety and management
- Credibility in rare indications
CMOs and supply partners
InflaRx N.V. depends on CMOs and supply partners because vilobelimab is an intravenous monoclonal antibody, so it needs biologics manufacturing, fill-finish, cold-chain handling, and release testing. INF904 and IFX002 also add chemistry, manufacturing, and analytical support, which helps keep study drug supply steady and quality control tight across trials.
Key point: for a biotech with multiple clinical assets, these partners reduce batch risk and protect trial timelines. They also support GMP-based production and assay validation, which is critical when one delayed lot can slow enrollment or data readout.
- Biologics manufacturing for vilobelimab
- Chemistry and analytical support for INF904
- Supply continuity for IFX002 studies
- Quality control and GMP release testing
InflaRx’s Key Partnerships Help De-Risk Trials and Speed Development
InflaRx N.V.’s key partnerships center on Merck & Co. Inc. for oncology trial support, Beijing Defengrei Biotechnology Co. Ltd. for China co-development, plus clinical sites, specialist investigators, and CMO/supply partners that keep studies, safety oversight, and biologics supply moving. These links reduce execution risk and help protect trial timelines across vilobelimab, INF904, and IFX002.
| Partner | Role |
|---|---|
| Merck & Co. Inc. | Oncology trial support |
| Beijing Defengrei Biotechnology Co. Ltd. | China co-development |
| CMOs | Manufacturing and supply |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for InflaRx N.V. covering its biotech strategy, stakeholders, and value creation.
Customizable Excel Spreadsheet
InflaRx N.V. Business Model Canvas quickly maps how it addresses key unmet medical needs with a clear, editable one-page view.
Reference Sources
Helps validate InflaRx N.V. claims fast with traceable sources, strengthening credibility and decision-making confidence.
Activities
C5a inhibitor discovery
InflaRx N.V.’s core activity is C5a inhibitor discovery, using its C5a technology to block inflammatory signaling tied to autoimmune and inflammatory diseases. This scientific platform underpins its lead candidate vilobelimab, which reached Phase 3 testing, making the company’s research engine the main value driver.
Vilobelimab clinical development
Vilobelimab is InflaRx N.V.’s lead asset and a first-in-class anti-C5a monoclonal antibody. It has completed 1 Phase III study in hidradenitis suppurativa and is still advancing in multiple Phase II and Phase IIa programs, so clinical execution remains the main value driver.
INF904 pipeline advancement
INF904 is InflaRx N.V.’s oral small-molecule lead for chronic inflammatory and autoimmune diseases, and moving it through early-stage testing is a core R&D task. In 2025, this pipeline work remained a key spend driver as the Company focused resources on advancing one main clinical asset and building proof-of-concept data.
IFX002 preclinical work
IFX002 is in preclinical work, so InflaRx N.V. must prove the target, test pharmacology, and run safety studies before first human dosing. This adds a third pipeline leg alongside vilobelimab and INF904, which helps reduce single-asset risk.
As of the latest public filings, InflaRx N.V. reported cash and cash equivalents of about €12.8 million and R&D expense of about €13.7 million for 2024, so preclinical discipline matters.
- Target validation first
- Pharmacology before clinic
- Safety studies are key
- Broadens the pipeline
Regulatory and trial operations
InflaRx N.V. must run ethics reviews, regulatory filings, safety reports, and study oversight to keep Phase II and Phase III work moving in the U.S. and Europe. For example, its Phase 3 vilobelimab program in pyoderma gangrenosum and hidradenitis suppurativa depends on these controls to support future approval and labeling work.
- Phase II/III trial compliance in U.S. and Europe
- Safety reporting and ethics oversight
- Supports approval and label claims
InflaRx Advances C5a Pipeline with 2025 Trial and Filing Progress
InflaRx N.V. centers its work on C5a-blocking R&D, advancing vilobelimab, INF904, and IFX002 through target validation, preclinical studies, and Phase II/III trials. In 2025, key work stayed on trial execution, safety reporting, and regulatory filings across the U.S. and Europe.
| Key activity | 2025 focus |
|---|---|
| R&D engine | C5a platform |
| Clinical ops | Phase II/III trials |
| Regulatory | Safety and filings |
What You See Is What You Get
Business Model Canvas
The InflaRx N.V. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a sample or mockup—this is a live view of the final file, complete in the same professional format. Once your order is complete, you’ll unlock the full version of this same document, ready to download and use.
Resources
Vilobelimab asset
Vilobelimab is InflaRx N.V.’s lead clinical asset and a first-in-class intravenous anti-C5a monoclonal antibody. It remains the company’s main near-term value driver, with development focus concentrated on late-stage inflammation programs built around C5a blockade.
C5a technology platform
The C5a-focused discovery platform is InflaRx N.V.'s core intellectual asset, built on C5a biology to connect inflammation science to multiple autoimmune and inflammatory uses. It supports both current programs and future pipeline generation, with vilobelimab as the main C5a-linked clinical asset.
Pipeline assets
InflaRx N.V.'s main key resource is its 3 disclosed pipeline programs: vilobelimab, INF904, and IFX002. That mix gives the Company optionality across clinical, preclinical, and oral small-molecule development, with vilobelimab as the lead asset and the pipeline as the core strategic value driver.
Clinical data package
InflaRx N.V.'s clinical data package is a core asset: completed and ongoing studies generate human efficacy and safety data, with the Phase III hidradenitis suppurativa program and ongoing Phase II studies carrying the most weight. These data sets underpin partnering talks, financing needs, and regulatory filings.
- Phase III HS data is the key value driver.
- Ongoing Phase II work keeps the pipeline active.
- Human safety data supports regulators and partners.
Jena and U.S. operating base
InflaRx N.V. is headquartered in Jena, Germany, and also keeps a U.S. operating base, giving it a dual footprint for European and U.S. development work. That setup supports global clinical trial execution, regulatory coordination, and partnership management across both markets.
- Jena: core R&D and corporate base
- U.S.: clinical and partner-facing operations
InflaRx’s Core Assets Power Its Clinical Pipeline and Global Reach
InflaRx N.V.'s key resources are vilobelimab, the C5a antibody platform, and its 3 disclosed programs: vilobelimab, INF904, and IFX002. The Jena, Germany base and U.S. operating footprint support trial work, regulatory filings, and partnering.
| Resource | Why it matters |
|---|---|
| Vilobelimab | Lead clinical asset |
| C5a platform | Pipeline engine |
| Jena and U.S. base | Global execution |
Value Propositions
First-in-class anti-C5a therapy
Vilobelimab is InflaRx N.V.'s first-in-class anti-C5a monoclonal antibody, targeting a key inflammatory mediator that drives autoimmune and inflammatory disease progression. In phase 3 ZEPHYRUS-1, 21% of patients achieved complete wound healing at week 16 versus 0% on placebo, showing clear scientific differentiation.
Rare disease focus
InflaRx N.V. targets rare, severe diseases like hidradenitis suppurativa, AAV, and pyoderma gangrenosum, where specialist-led care and few approved options support premium pricing. Hidradenitis suppurativa affects about 1% of people, while AAV incidence is roughly 10 to 20 per million each year.
Oncology resistance setting
Vilobelimab is being tested in PD-1/PD-L1 inhibitor resistant or refractory cutaneous squamous cell carcinoma, a hard-to-treat setting where options are limited. In the U.S., about 200,000 cSCC cases are diagnosed each year, and checkpoint resistance can leave patients with few effective therapies, so this gives InflaRx N.V. a clear differentiated oncology use case.
Multi-asset inflammation pipeline
InflaRx N.V. is not tied to one molecule: its inflammation pipeline spans the C5a/C5aR axis with C5a inhibitor vilobelimab, oral candidate INF904, and preclinical IFX002, which reduces single-asset risk and supports longer pipeline life. The company reported 2 clinical-stage programs and 1 preclinical asset in its latest public pipeline view, giving it more shots at value creation.
- Multi-asset exposure lowers concentration risk.
- INF904 adds an oral path.
- IFX002 extends preclinical depth.
Mechanism-based inflammation control
InflaRx N.V.’s C5a blockade aims to stop downstream inflammatory activation at an upstream node in the complement system, which has 5 core proteins and feeds many autoimmune and chronic inflammatory pathways. The value is broad biological reach with focused clinical execution in diseases where one mechanism can drive multiple inflammatory signals.
- C5a blocks upstream inflammation
- Relevant across many diseases
- Single target, focused trials
InflaRx’s vilobelimab shows breakthrough promise in rare inflammatory disease
InflaRx N.V. offers a first-in-class C5a blocker in vilobelimab, aiming to shut down upstream inflammation in severe, underserved disease. In phase 3 ZEPHYRUS-1, 21% of hidradenitis suppurativa patients reached complete wound healing at week 16 versus 0% on placebo.
Its value is strongest in rare, specialist-led settings like AAV and cSCC, where few approved options support premium pricing and faster adoption.
| Program | Key value |
|---|---|
| vilobelimab | 21% vs 0% |
| HS prevalence | ~1% |
| AAV incidence | 10-20/million |
Customer Relationships
Protocol-driven trial engagement
InflaRx N.V.’s customer relationships are built around clinical trials, with patients and sites tied to strict protocols, informed consent, and monitored follow-up. This is a high-touch, regulated model, and it matters more as the company concentrates resources on a small pipeline and trial execution rather than broad commercial sales.
Specialist investigator support
InflaRx’s customer ties sit with disease specialists who recruit, monitor, and retain patients in its clinical trials, not with consumers. In its latest annual reporting, R&D remained the main cost driver, so these scientific site links matter for trial quality, endpoint integrity, and data credibility.
B2B collaboration management
InflaRx N.V. manages B2B collaboration with two strategic partners, Merck and Beijing Defengrei, through formal agreements, supply planning, and joint development talks. This partnership-heavy model needs tight scientific and business coordination to keep programs aligned and move milestones on time.
Regulatory interaction
InflaRx N.V. keeps active regulator contact during development, with meetings on study design, safety reporting, and approval paths. For a clinical-stage biopharma with 0 marketed products and 1 lead late-stage asset, these touchpoints are key to de-risking trials and filings.
- Aligns protocols before enrollment
- Tracks safety in real time
- Shapes approval strategy early
Medical and scientific communication
InflaRx N.V. uses publications, trial updates, and conference readouts to keep clinicians and partners aligned on its C5a biology story; the tie is evidence-led, not brand-led. In FY2024, the company’s focus stayed on vilobelimab and its clinical data package, which is the core of trust building.
- Peer-reviewed data drives credibility
- Conference updates shape partner dialogue
- Clinical evidence matters more than branding
InflaRx Builds Trust Through Tight Clinical Discipline
InflaRx N.V. keeps customer ties tight and scientific: patients, trial sites, regulators, and partners all sit inside a controlled clinical network. With 0 marketed products, 1 late-stage asset, and 2 strategic partners, trust depends on protocol discipline, safety reporting, and clean data.
| Key link | Latest fact |
|---|---|
| Marketed products | 0 |
| Late-stage asset | 1 |
| Strategic partners | 2 |
Channels
Clinical trial sites
Clinical trial sites are InflaRx N.V.'s main channel to reach patients, enroll them, dose study drugs, and collect outcome data. As a clinical-stage company with no commercial product sales in 2025, this site network is the core path from R&D spend to proof of efficacy and safety.
Strategic partner networks
Merck and Beijing Defengrei are InflaRx N.V.'s key external development channels, giving the company 2 partner links for trial execution, supply, and local collaboration. This keeps InflaRx from funding a full commercial buildout; in 2025, that lean model mattered as the company stayed focused on development-stage spend and partner-led reach.
Scientific publications
InflaRx N.V. uses scientific publications and study disclosures to share trial data, which matters in rare disease and oncology, where over 300 million people live with a rare disease worldwide. This channel helps build trust with physicians, investigators, and investors by putting clinical results into peer-reviewed, public view.
Medical congresses
Medical congresses are a key channel for InflaRx N.V. to present clinical data to specialist audiences in dermatology, immunology, rheumatology, and oncology. They help build awareness before commercialization by placing trial results in front of prescribers, researchers, and payers at high-impact meetings where peer review and adoption often start.
- Reaches 4 specialist fields.
- Shares clinical results early.
- Supports pre-launch awareness.
Investor and corporate communications
As a Nasdaq-listed public company, InflaRx N.V. uses investor relations and corporate updates to share pipeline milestones, trial readouts, and partnership news. These channels keep the market informed, support financing efforts, and raise visibility with investors and potential partners.
- Shares milestones and trial progress.
- Supports fundraising and market trust.
- Highlights partnerships and strategy.
InflaRx Stays Lean, Driving 2025 Progress Through Trials and Partnerships
InflaRx N.V. channels its 2025 development efforts through clinical trial sites, partner links, congresses, publications, and investor relations. With 0 product sales and 2 key external partners, the company stays lean while moving data from patients to regulators, doctors, and capital markets.
| Channel | 2025 data |
|---|---|
| Clinical sites | Core trial access |
| Partners | 2 key links |
| Commercial sales | 0 |
| Public disclosure | IR, papers, congresses |
Customer Segments
Hidradenitis suppurativa patients
Hidradenitis suppurativa patients are a core rare inflammatory skin disease segment for vilobelimab. HS affects about 1% of people in many populations, and InflaRx’s Phase III program is aimed directly at this group, with dermatology specialists and treatment centers as the main access points for diagnosis, referral, and enrollment.
AAV patients
AAV patients are a rare, high-need autoimmune group, with ANCA-associated vasculitis affecting about 20 to 40 people per million each year in Western markets. InflaRx is testing vilobelimab in a Phase II study in this indication, targeting a severe population with organ- and life-threatening inflammation.
PD-1 or PD-L1 resistant CSCC patients
InflaRx targets patients with locally advanced or metastatic cutaneous squamous cell carcinoma who have relapsed after PD-1 or PD-L1 checkpoint inhibitors, a specialist oncology group with few options and high unmet need. These resistant or refractory patients form a small but high-value segment, since advanced CSCC can be life-threatening and often needs care from expert oncology centers.
Pyoderma gangraenosum patients
Pyoderma gangraenosum is a rare, chronic inflammatory skin disorder and an exploratory Phase IIa target for InflaRx N.V. The patient pool is small, but the need is high because lesions are painful, ulcerative, and hard to treat, which fits InflaRx N.V.'s rare-disease and inflammation focus.
- Rare but high unmet need
- Phase IIa, exploratory market
- Strong fit with inflammation focus
Biopharma partners and clinicians
InflaRx N.V. serves biopharma partners, investigators, and future prescribing specialists first, because it is still pre-commercial. In 2025, it reported no product revenue, so value is being built through trial networks and clinical data before payers and treating physicians enter the model.
That segment mix fits a clinical-stage Company: partners fund, test, and de-risk the asset now, then clinicians and payers matter later at launch.
- Partners drive early validation
- Investigators run the trials
- Physicians matter at launch
- Payers matter after approval
InflaRx Targets Rare, Severe Inflammation With No Product Revenue Yet
InflaRx N.V. serves small, high-unmet-need patient groups: hidradenitis suppurativa, ANCA-associated vasculitis, refractory cutaneous squamous cell carcinoma, and pyoderma gangraenosum. In 2025, it had no product revenue, so customers are still trials, investigators, and future prescribers; payers matter only after approval.
| Segment | Key fact |
|---|---|
| Patients | Rare, severe inflammation |
| Partners/clinicians | Drive trials, then launch |
Cost Structure
Clinical trial spend
Clinical trial spend is InflaRx N.V.’s biggest cost item: patient enrollment, site fees, monitoring, data management, and safety follow-up. In biopharma, Phase II studies often run about $7 million to $20 million, while Phase III can reach $20 million to $100 million+, so every program choice has a direct cash impact.
R and D personnel
InflaRx’s R and D personnel—scientists, clinicians, regulatory staff, and development ops—are a core cost line, because they fund discovery, study management, and data reads. In biopharma, payroll often drives most cash burn; InflaRx reported 2024 research and development expenses of €26.1 million.
Manufacturing and supply
Vilobelimab is an IV biologic, so InflaRx N.V. must fund drug substance and drug product supply, plus GMP release and cold-chain logistics. INF904 and IFX002 add CMC and analytical development costs, and manufacturing support is needed now for clinical supply and later for commercial readiness.
Regulatory and quality
Regulatory and quality costs are non-discretionary for InflaRx N.V. because every clinical step needs compliance, pharmacovigilance, QA, and filings; these spend lines usually rise as programs move from Phase 1 to later stages and into more geographies, with no easy cut if timelines slip.
- Compliance and safety monitoring are fixed needs
- QA rises with each trial and market filing
- More countries mean higher submission cost
Public company overhead
As a Nasdaq-listed biopharma with U.S. and German operations, InflaRx N.V. carries steady governance, legal, finance, audit, and SEC/IFRS reporting costs. That overhead is not just admin drag: it supports market access, board control, and cross-border compliance. One listed-company rule set, two jurisdictions.
- Governance and audit costs
- SEC and German reporting
- U.S.-Germany admin load
- Supports capital access
InflaRx’s €26.1M R&D Bill Shows How Fast Trial Costs Escalate
InflaRx N.V.’s cost base is still dominated by clinical trials, CMC/manufacturing, and R and D staff. It reported 2024 research and development expenses of €26.1 million, showing how fast cash burn scales with trial activity and biologic supply needs.
| Cost line | Key data |
|---|---|
| R and D | €26.1m in 2024 |
| Phase II / III trials | $7m-$20m / $20m-$100m+ |
Revenue Streams
Collaboration revenue
InflaRx N.V. can earn collaboration revenue from its clinical trial collaboration and supply agreement with Merck, which can include shared trial and supply reimbursements. In 2025, this stream helped offset part of InflaRx N.V.’s R&D burden while it advanced its pipeline, but the company did not break out a large recurring collaboration fee base.
Co-development income
InflaRx N.V. still had no product sales in 2025, so co-development income stays a key pre-commercial revenue stream. The Beijing Defengrei agreement adds a partnering path that can bring shared development funding, upfront cash, and milestone-linked consideration before launch.
Milestones and licensing
InflaRx’s revenue stream here is mostly non-product: biopharma deals can bring upfront cash, then development milestones and later licensing or royalty payments as pipeline assets advance. That matters for a clinical-stage company like InflaRx, which still depends on collaboration income before product sales scale.
Supply and service income
InflaRx N.V.'s supply and service income can come from clinical supply deals, where a partner pays for or reimburses study material before any product launch. This is usually small and temporary, but it can help offset R&D cash burn while a program is still in trials.
- Partner funds clinical trial materials.
- Revenue usually appears pre-launch.
- Offsets part of R&D spend.
Future product sales and royalties
InflaRx N.V. had no marketed product revenue in its latest filings, so this stream is still pre-commercial. If vilobelimab or another asset wins approval, future product sales could become the main revenue driver; royalties could add a second layer if InflaRx licenses assets or territories.
- 2025 marketed product revenue: $0
- Upside depends on approvals
- Licensing can add royalties
InflaRx Revenue Stays Pre-Commercial, Backed by Partner Cash
InflaRx N.V.’s 2025 revenue was still pre-commercial: no product sales, so income came mainly from collaboration and supply reimbursements. Merck and Beijing Defengrei can add upfront cash, milestone payments, and later royalties if pipeline assets advance.
| 2025 | Revenue |
|---|---|
| Product sales | $0 |
| Main streams | Collab, supply, milestones |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.